Kamada (NASDAQ:KMDA) Ltd. released its financial results for the third quarter and first nine months of 2023, showing significant growth and a positive outlook for the remainder of the year. The company's total revenues for the nine months reached $106.1 million, marking a 26% year-over-year increase. Kamada's adjusted EBITDA for the same period rose by 67% to $17.7 million. The company also reiterated its full-year revenue guidance of $138 million to $146 million and adjusted EBITDA guidance of $22 million to $26 million.
Key takeaways from the earnings call include:
- Kamada's anti-rabies immunoglobulin, KEDRAB, has seen significant growth in the US market due to label expansion and increased demand.
- The company has paid off its existing bank loan and is now debt-free.
- Kamada's plasma collection company, Kamada Plasma, is expanding its collection capacity and plans to open a second collection center early next year.
- The company is also progressing with its Phase 3 clinical trial for inhaled Alpha-1 Antitrypsin therapy and has received positive feedback from the independent Data and Safety Monitoring Board.
- Kamada's total cash position as of September 30, 2023, was $52.6 million.
In Q3 2023, Kamada reported a net income of approximately $3.2 million, or $0.06 per share, compared to $500,000, or $0.01 per share, in the same period the year before. The company's cash provided by operating activities in Q3 2023 was $900,000, down from $5.5 million in Q3 2022. However, Kamada's total cash position as of September 30, 2023, was $52.6 million, bolstered by $58.2 million in net proceeds from a financing deal.
During the earnings call, Kamada Ltd . provided updates on their early-stage programs, including the development of immunoglobulins from convalescent plasma. These programs are currently in preclinical studies, with plans to start clinical studies in 2025. The company also highlighted the success of their KEDRAB product and the growth of their four FDA-approved products internationally.
With the recent closing of a $60 million financing, Kamada is actively seeking business development opportunities, particularly in the transplantation field, to further grow their business. The company expressed satisfaction with their performance and commitment to creating long-term shareholder value.
InvestingPro Insights
InvestingPro's real-time data and tips offer some valuable insights into Kamada Ltd.'s performance and future prospects. According to InvestingPro, Kamada's revenue growth has been accelerating, which aligns with the company's Q3 2023 results. Furthermore, Kamada is trading at a low P/E ratio relative to near-term earnings growth, indicating that the stock might be undervalued.
InvestingPro data also reveals that Kamada's revenue growth in the last twelve months as of Q2 2023 was 37.31%, further confirming the company's strong financial performance. The company's P/E ratio stands at 62.7, and its adjusted P/E ratio for the last twelve months as of Q2 2023 is 36.98.
InvestingPro Tips also suggest that Kamada's net income is expected to grow this year, which is consistent with the company's positive outlook for the remainder of the year. Additionally, Kamada operates with a moderate level of debt, which aligns with the company's recent announcement of achieving a debt-free status.
These insights, along with over 200 additional tips, can be found on the InvestingPro platform, providing users with comprehensive data and tips to make informed investment decisions.
Full transcript - KMDA Q3 2023:
Operator: Good day ladies and gentlemen and welcome to Kamada Ltd.'s Third Quarter 2023 Earnings Conference Call. At this time, all participants are in listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, this conference call is being recorded. I will now turn the conference over to Mr. Brian Ritchie. Please go ahead sir.
Brian Ritchie: Thank you. This is Brian Ritchie with LifeSci Advisors. Thank you all for participating in today's call. Joining me from Kamada are Amir London, Chief Executive Officer; and Chaime Orlev, Chief Financial Officer. Earlier today, Kamada announced its financial results for the three and nine months ended September 30, 2023. If you have not received this news release, please go to the Investors page of the company's website at www.kamada.com. Before we begin, I would like to caution that comments made during this conference call by management will contain forward-looking statements that involve risks and uncertainties regarding the operations and future results of Kamada. I encourage you to review the company's filings with the Securities and Exchange Commission, including, without limitation, the company's Forms 20-F and 6-K, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, Monday, November 13, 2023. Kamada undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this conference call. With that said, it's my pleasure to turn the call over to Amir London, CEO. Amir?
Amir London: Thank you, Brian, and thanks also to our investors and analysts for your interest in Kamada and for participating in today's call. To begin, I'd like to indicate that the company continues to conduct its business operations in Israel with no effect on business continuity and its global supply of products is not expected to be interrupted as a result of the recent events in Israel. With that, I'll now give up to the strong financial and operational momentum throughout our business that has us well positioned to achieve our 2023 full year guidance, which I will discuss momentarily. I'll begin with a high level review of our robust financial results for the first nine months of 2023. The total revenues of $106.1 million which were presented year-over-year growth of 26% and adjusted EBITDA of $17.7 million, an increase of 67% as compared to the first nine months of 2022. We achieved the top and bottom line growth anticipating our business in the first nine months of the year. We continue to effectively leverage the multiple growth drivers in our business including a significant increase in KEDRAB sales to Kedrion for distribution in the U.S. market, the portfolio of four FDA-approved immunoglobulins acquired in late 2021, CYTOGAM, HEPAGAMB, VARIZIG and WINRHO, and our Israeli distribution business. Looking ahead, we expect the momentum for the first nine months of the year to extend to the fourth quarter of 2023 with annual profitability to be increased as compared to last year. As such, we are reiterating our full year 2023 revenue guidance of $138 million to $146 million and adjusted EBITDA of $22 million to $26 million. The midpoint of that range would represent profitability growth of approximately 35% of the 2022. To reiterate what we have said previously, beyond 2023 we continue to anticipate annual double digit revenue and profitability growth in the foreseeable years ahead with significant upside potential and limited downside risk. While I noted our multiple growth drivers earlier, KEDRAB our anti-rabies immunoglobulin has been especially impactful during the first nine months of 2023, a trend we expect to continue in the fourth quarter and beyond. Throughout the first nine months of 2023, we experienced a significant increase in demand for the products in the U.S. and we anticipate the continuation of this momentum moving forward. The significant market share growth demonstrated by KEDRAB is being driven by Kedrion's excellent commercial activity and thanks to the FDA approval obtained in 2021 for the label expansion for the product that has differentiated it as the first and only human rabies immunoglobulin available in the U.S. market to be clinically studied in children.
Funds: While Chaime will discuss the next process for the private placement in more detail shortly, I would like to highlight that the result of this transaction, we're also able to pay down the entire remaining outstanding balance of our existing bank loan and we are now debt free. Well moving on, our U.S. team established during 2022 continues to achieve steady progress in promoting of specialty IDG portfolio to physicians and other healthcare practitioners through our direct engagement and opportunity at medical meetings. As we've said previously, our activities promoting these important therapies primarily CYTOGAM and VARIZIG represent the first time in over a decade that these hyper immunoglobulins specialty products have been supported by field based activity in the U.S.
Behring: We have also recently established our first Scientific Advisory Board consisting of eight U.S. based world renown thought leaders in the solid organ transplantation field. The Advisory Board focused on our newly implemented U.S. clinical program for CYTOGAM including new opportunities and future research and development possibilities. As we said will be the case, key U.S. positions are beginning to proactively support the use of this product, starting with CYTOGAM, which was the subject of a poster presentation at the recently held IDWeek 2023 in Boston. At this important medical meeting results were presented of an investigative initiated five-year retrospective study consisting of 325 lung transplant patients evaluating the real world use of CYTOGAM in combination with antiviral agents for the prevention of CMV disease in high risk CMV mismatched lung transplant recipients.
Fernando Torres: Moving on, looking further ahead as future catalyst, we continue to be pleased with the progress made at Kamada Plasma, our U.S. based plasma collection company. Our 2021 acquisition of a plasma collection center in Houston, Texas represented Kamada's entry into the U.S. plasma collection market and supported our strategic goal of becoming a fully integrated specialty plasma product company. We continue to successfully expand the hyper immune plasma collection capacity at our first center and looking at opening our second collection center in Houston, Texas early next year. On the development side, enrollment continued to ramp up in our ongoing pivotal Phase 3 InnovAATe clinical trial for inhaled Alpha-1 Antitrypsin therapy for the treatment of Alpha-1 deficient patients. To date, we've enrolled over 30% of the overall required enrollment of the study. We have recently also received positive feedback from the independent Data and Safety Monitoring Board, the DSMB, which recommended study continuation without modification for the sixth time since the study was initiated based on encouraging safety data observed in the study to date. In addition as we reported on our last call, the European Medicine Agency, the EMA, has recently reconsidered our design of the ongoing study and acknowledged the statistically and clinically meaningful improvement in lung function measured by SED1 demonstrated in our previous Phase 2/3 European study. We continue to anticipate advancing our discussions with the FDA regarding study progress by end of this year. As a reminder, Kamada's investigational held AAT treatment is a noninvasive at-home treatment, with an expected better ease-of-use and quality of life for alpha-1 deficient patients as compared to the current IV standard of care. The health product is the leading new innovative alpha-1 deficiency treatment in advanced clinical stage, and it represents a substantial opportunity to be a transformational product in a market that is already over $1 billion in annual sales in the U.S. and the EU. Finally, I'd like to formally welcome Prof. Benjamin Dekel and Assaf Itshayek, who were recently appointed as independent directors on our Board. Prof. Dekel is known internationally as one of the most innovative and highly recognized researchers in the field of human renal stem cell biology and regenerative medicine. Assaf Itshayek has over 15 years of high-tech industry experience in senior management and finance executive positions. We look forward to leveraging the scientific and financial expertise of these highly accomplished individuals as we continue advancing our existing business and pipeline and evaluate potential new opportunities. With that, I'll now turn the call over to Chaime for a detailed discussion of our financial results in the third quarter and the first nine months of 2023. Chaime, please go ahead.
Chaime Orlev: Thank you, Amir, and good day, everyone. We're happy to report a significant year-over-year increase in revenues and profitability for the third quarter and first nine months of 2023. Total revenues for the third quarter were approximately $37.9 million. And for the nine months of 2023, total revenues were $106.1 million, an increase of 18% and 26%, respectively. The year-over-year growth was primarily driven by increased sales of KEDRAB to Kedrion, due to increased demand for the product in the U.S. market. Total gross profit for the third quarter of 2023 was $14.8 million, representing 39% margin compared to $12.9 million or a 40% margin in the third quarter of 2022. Total gross profit for the first nine months of 2023 was $41.1 million, representing a 39% margin, compared to $31.4 million or a 37% margin in the first nine months of 2022. As previously discussed, the company is accounting for depreciation expenses associated with intangible assets, which were generated through the late 2021 acquisition of our IgG products. The company's cost of goods sold and sales and marketing expenses includes approximately $1.3 million and $400,000, respectively, of such depreciation expenses per quarter. Operating expenses, including R&D, sales and marketing, G&A and other expenses, totaled $10.4 million in the third quarter of 2023 compared to $10.3 million in the third quarter of 2022. Operating expenses for the first nine months of 2023 totaled $33.8 million, an increase of approximately 9% over the prior year period. The increase, as compared to 2022, is related to the advancement of our commercial activity as well as our Phase 3 InnovAATe trial. As we did throughout 2022, we continue to account for financing expenses with respect to the revaluation of contingent consideration and the long-term assumed liability, all of which are related to the acquisition completed in 2021. Net income for the third quarter of 2023 was approximately $3.2 million or $0.06 per share on a fully diluted basis as compared to a net income of $500,000 or $0.01 per share in the prior year period. Adjusted EBITDA was $7.9 million for the third quarter of 2023, up 31% as compared to the $6 million in the third quarter of 2022. For the first nine months of 2023, adjusted EBITDA was $17.7 million, up 67%, as compared to the $10.6 million in the first nine months of 2022. As Amir highlighted earlier, we are reiterating our full year 2023 revenue guidance of $138 million to $146 million and adjusted EBITDA guidance of $22 million to $26 million. The midpoint of such range represents approximately 35% growth as compared to fiscal year 2022. Finally, cash provided by operating activities was $900,000 in the third quarter of 2023 as compared to cash provided by operating activities of $5.5 million in the third quarter of 2022. Our total cash position as of September 30, 2023, was $52.6 million as compared to $34.3 million on December 31, 2022. This includes $58.2 million of net proceeds from the previously announced $60 million financing, which closed in September of 2023. In addition, during the quarter, we paid a total of $17.4 million to close the outstanding balance of the bank loan, and $11.5 million was used for old milestone payments. These actions are reflected in our cash balance as of September 30, 2023. Importantly, as Amir noted, we are now debt-free. Before proceeding to take your questions, I would like to also note that we filed today the notice of the company's Annual General Meeting to be held on Thursday, December 28. We will now open the call for questions. Operator?
Operator: Thank you, sir. [Operator Instructions] Our first question comes from Annabel Samimy of Stifel. Please go ahead.
Annabel Samimy: Hi guys. Thanks for taking my question and good quarter. So I just wanted to understand some of the dynamics for Kedrion. You're obviously seeing some very significant growth there. Could you tell us -- it's been approved for some time. So can you tell us what do you think the key underlying drivers are? Is it primarily the label change? Is there something else that's driving that underlying growth refocus on the sales? And can we depend on that consistent growth in those consistent trends going into the next couple of years? Thank you.
Amir London: Hi. Annabel, thank you for the question. We believe there are multiple dynamics in the market, which positively affect the significant growth of the KEDRAB market share. It has to do with the label expansion that we have received and that we have implemented last year -- end of 2021 into 2022, and then the impact of this into 2023. Of course, the end of the pandemic and the fact that the overall market has gone back to where it was prior to the pandemic, this also has a significant effect. The excellent work done by our partner, Kedrion, in the U.S. market with a very wide coverage reaching almost every hospital in America, and being able to promote the product and its benefits. And also, there was another product that was in the market until late last year, which exited the market, and we are able to take a significant market share from that exit of that product.
Annabel Samimy: Okay. Great. And anything that you can update us on regarding some pipeline efforts that you have going on?
Amir London: Pipeline efforts, that's the questions?
Annabel Samimy: Anything in the pipeline that you have any updates with regard to the clinical studies, that you're enrolling right now, for the AAT indication or any selections from early-stage programs that you are willing to take forward?
Amir London: Yes, yes. So main effort is, of course, a round in held AAT - Chaime has spoke about it on the call. So we are advancing the improvement to the study and discussion with the regulators, and we had a very positive discussion with EMA. We expect to have a similar discussion with the FDA before year-end. We had six successful DSMB meetings recently, which has kind of validated the excellent safety to our side of the product and the safety data that we are accumulating from the current study. In addition, we do have three early step development programs of other plasma-derived products that we have discussed in previous calls. We have a product, which is a plasma eye drops, that is a preclinical stage. We have an anti-tuberculosis immunoglobulin product, which is in preclinical development. And we have a device that we are developing, we call it jet immune, which is an automated portable small scale system for extracting and to refining high premium immunoglobulins from convalescent plasma. So these are the three early-stage programs, which are under development. Once we make some material progress, we will update. All of them are in preclinical studies, and we hope to start clinical studies in 2025 for the three products.
Annabel Samimy: Okay. Great. Thank you so much.
Operator: Thank you. Ladies and gentlemen at this stage, I hand you over to Brian Ritchie for questions from the webcast. Thank you.
Brian Ritchie: Thank you. A couple of questions that have come in off the web. First, at various points of the year, as you've already talked about, KEDRAB has been the driver. Prior to that, you talked about the four products – the four IgG products being the primary driver. It seems like there's a lot of diversity in your business, if you will. Maybe Amir talk a little bit about that, if you could.
Amir London: Yes. Kamada's business is very healthy, if I may use this term. I think we continue to effectively leverage multiple growth drivers in our business. So as we mentioned, KEDRAB has been growing significantly with an increase in market share. We also see a nice international growth of the four FDA-approved products required late 2021. We are investing in the medical, clinical and commercial activities around CYTOGAM and VARIZIG in the U.S. market, with the commercial and medical team was established in the U.S. And we have our Israeli distribution business, which is growing. So all of that, if I may, it's like a nice metric of products and territories that each one of them is contributing to overall growth. And looking forward, into 2024 and beyond, we expect this growth to continue with the multiple growth drivers that we own.
Brian Ritchie: Thanks, Amir. Another question that's come in. Now that the private placement has closed, maybe talk a little bit about what you'll be looking for from a business development standpoint and potentially looking to add?
Amir London: Yes. So with the additional funds, thanks to the FIMI investment, we are proactively looking to add some business development initiatives. We are looking to leverage the commercial infrastructure that we have established in the U.S. market to bring in, to acquire, or to in-license additional products. This could be either primarily in the transplantation field, where we are currently mainly focused on specialty plasma products. And we are as I mentioned, we are proactively looking at opportunities, and we are screening the different assets, which are brought to us. And hoping that in the future, we will be able to close such a transaction, which will help us to continue growing the business, in addition to the organic growth I just talked about, so also to grow through an M&A.
Brian Ritchie: Terrific. Thank you, Amir. And with that, I'll pass the call back over to you for any closing remarks.
Amir London: Thank you, Brian. So in closing, we are pleased with our solid performance during the first nine months of the year. We are excited about the potential opportunities that lie ahead following the closing of the $60 million financing. We look forward to continuing to support clinicians and patients with the important lifesaving products that we develop and commercialize and we thank you all, you investors for the support and remain committed to creating long-term shareholder value. Thank you all and we hope you all stay healthy and safe. Thank you.
Operator: Thank you, sir. Ladies and gentlemen, that concludes today's event. Thank you for joining us and you may now disconnect your line.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.